Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kapildeo Lotun

Interventional Cardiology Tucson, AZ Medical Doctor

NPI 1265510796 CMS profile 12611

1501 N Campbell Ave, Sarver Heart Center, Tucson, AZ 85724

Open in the dashboard

General payments

$365,367

836 records reported · program years 2019–2025

Research payments

$50

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$122,423 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kapildeo Lotun of Tucson, AZ is reported in the CMS Open Payments database as having received $365,367 across 836 general payments and $50 in research payments paid to them. Separately, studies naming them as principal investigator received $122,423 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52,550 157
2024 General $54,542 180
2024 Research $50 1
2023 General $38,930 114
2022 General $23,686 101
2021 General $17,333 55
2020 General $50,216 65
2019 General $128,110 164

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kapildeo Lotun
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Kapildeo Lotun were reported at $52,550. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Kapildeo Lotun Interventional Cardiology median Middle half National median
2019 $128,110 $1,097 $329–$3,048 $163
2020 $50,216 $473 $161–$1,480 $114
2021 $17,333 $677 $233–$1,827 $132
2022 $23,686 $978 $333–$2,724 $149
2023 $38,930 $1,136 $382–$2,986 $160
2024 $54,542 $1,181 $395–$3,326 $164
2025 $52,550 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $156,384 280 payments
  2. Medtronic Vascular, Inc. $96,545 103 payments
  3. LivaNova USA, Inc. $35,280 25 payments
  4. Edwards Lifesciences Corporation $33,910 144 payments
  5. Boston Scientific Corporation $20,209 105 payments
  6. Abiomed $15,399 31 payments
  7. Abbott Laboratories $3,317 61 payments
  8. Shockwave Medical, Inc $741 27 payments
  9. Terumo Medical Corporation $403 6 payments
  10. Philips Electronics North America Corporation $361 8 payments
  11. Other $2,819 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $227,083 53 payments
  2. Travel and Lodging $77,005 156 payments
  3. Food and Beverage $24,911 618 payments
  4. Consulting Fee $24,344 6 payments
  5. Honoraria $12,000 2 payments
  6. Education $25 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $129,216 220 payments
  2. CoreValve Evolut Transcatheter Valve Systems $86,685 77 payments
  3. TandemLife $35,233 24 payments
  4. Edwards SAPIEN 3 Transcatheter Heart Valve $29,011 41 payments
  5. Impella $15,317 30 payments
  6. CoreValve Evolut Transcatheter Valve Systems $15,171 11 payments
  7. General - Vascular Access $10,863 6 payments
  8. Resolute $8,219 14 payments
  9. PASCAL $1,587 24 payments
  10. TRAcelet $1,584 8 payments
  11. Other $16,155 327 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $50 1 payment

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$156,334

Medicare's payments for the services billed

Medicare patients

281

Average age 78

Services billed

1,073

117 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Heart failure 56%
Arthritis 51%
Atrial fibrillation 50%
Diabetes 43%
Chronic kidney disease 40%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
$122 — —
AMVUTTRA
$114 — —
JARDIANCE
$23 — —
VYNDAQEL
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

837 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record